Scientist II, Sustain & Support

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has launched liquid biopsy-based Guardant360®, Guardant360 CDx and GuardantOMNI® tests for advanced stage cancer patients. These tests fuel development of its LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.

To enable Guardant Health to lead the disruption of cancer treatments through non-invasive cancer screening, the Minimal Residual Disease (MRD) program is seeking a highly motivated Scientist to join the group’s Sustaining & Process Improvement team in the improvement and validation of novel technologies intended to revolutionize early-detection of residual disease via next-generation sequencing in a regulated environment. At Guardant, we leverage the most advanced technologies and work with leaders in many different fields to create the most impactful and meaningful technologies for cancer management.

As a Scientist in the MRD technology organization, you will interface with multiple teams including process engineering, clinical operations, research operations, and bioinformatics. You will be hands on in the lab and be required to design, improve, implement, and validate new technologies related to liquid biopsy sequencing assays for the early detection, treatment, and monitoring of all cancer types. You will play a critical role in developing the standards and metrics by which assay performance is monitored and maintained, and be responsible for developing existing assays as well as future product offerings.

Guardant's MRD program seeks to leverage our leadership in the field of liquid biopsy to address a core unmet need in clinical cancer care. Its success is being driven by a team of highly-motivated experts such as yourself, passionate about the potential to revolutionize the field of cancer diagnosis and management thus saving patient lives.

Essential Duties and Responsibilities:

• Be able to work in a team environment to develop, test and validate technologies with next-generation sequencing in both CLIA/CAP and FDA-regulated environments.
• Think creatively and apply knowledge to execute validation experiments and analyze data for NGS applications in oncology diagnostics
• Document product development requirements and validation results in the form of professional quality reports following Good Documentation Practices.
• Be highly committed and deliver results in a fast-paced start-up environment

• 5+ yrs similar Industry experience preferred
• Knowledge of sample preparation and next-generation sequencing technologies
• Deep technical knowledge of NGS library preparation and methods.
• Familiarity with commonly used bioinformatics tools in the analysis of NGS data
• Experience working with Liquid Handlers preferred ( Hamilton, Tecan, Agilent etc)
• Excellent interdisciplinary communication skills required
• Good organization skills, and detailed orientated

Education:

MS in Biology, Molecular Biology, Biochemistry, or similar fields with 5yrs + Industry experience preferred.

Covid Vaccination Policy: Starting January 7, 2022, Guardant Health will require all employees to be fully vaccinated to either (a) establish that they have been fully vaccinated against COVID-19; or (b) request and obtain an approved exemption from Guardant’s COVID-19 U.S. Vaccination Policy as a reasonable accommodation, as consistent with applicable laws. An employee is considered fully vaccinated against COVID-19 two weeks after receiving the second dose of a two-dose vaccine or one dose of a single-dose vaccination. Acceptable vaccines are approved or under emergency use authorization by the U.S. Food and Drug Administration (FDA) and/or the World Health Organization (WHO). In addition, fully-vaccinated employees will be required to maintain their fully-vaccinated status under this policy by obtaining, if applicable, any FDA-approved boosters.

Employee may be required to lift routine office supplies and use office equipment. Majority of the work is performed in a desk/office environment; however, there may be exposure to high noise levels, fumes, and biohazard material in the laboratory environment. Ability to sit for extended periods of time.

Guardant Health is an Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability.

All your information will be kept confidential according to EEO guidelines.

To learn more about the information collected when you apply for a position at Guardant Health, Inc. and how it is used, please review our Privacy Notice for Job Applicants.

Please visit our career page at: http://www.guardanthealth.com/jobs/

#LI-JD1